856-547-8004
713 Station Avenue, Haddon Heights, N.J. 08035
Haddon Heights Office
713 Station Avenue
Haddon Heights, N.J. 08035
Phone: 856-547-8004
Fax: 856-547-8377
Board Certified in Rheumatology & Fellow of the American College of Rheumatology
Hammonton Office
8 N. White Horse Pike
Suite 101
Hammonton, N.J. 08037
Phone : 609-567-1440
Clinical Research
Mark Fisher, M.D. F.A.C.R.
Dr. Mark Fisher is board certified in Rheumatology and is a Fellow of the American College of Rheumatology. He received his medical degree in 1973 from Hahnemann Medical College in Philadelphia, PA. He completed his residency program in Internal Medicine at Hahnemann Hospital. Dr. Fisher performed a fellowship in Rheumatology at Temple University Hospital in Philadelphia, PA.
In 1978, Dr. Mark Fisher opened a private practice specializing in Rheumatology, currently located in Haddon Heights, N.J. A satellite office was opened in Hammonton, N.J. in 1980.
Dr. Fisher has held teaching and administrative appointments. At present he serves as the Chief of the Division of Rheumatology at Our Lady of Lourdes Medical Center in Camden, NJ and Clinical Assistant Professor of Medicine Thomas Jefferson University Hospital in Philadelphia, PA.
For the past 25 years, Dr. Fisher has been involved in clinical research trials as a Primary Investigator. He has participated in phase 2, 3 and 4 clinical trials for osteoporosis, analgesics, NSAIDS COX2s for osteoarthritis and rheumatoid arthritis, GI tolerability, pain management, low back pain, and IV biologics for rheumatoid arthritis.
Fisher Clinical Research Facility
Fisher Clinical Research has a dedicated staff to assist with the patients’ needs. The office is conveniently located in Haddon Heights, NJ where it is easily accessible by I-295 and the White Horse Pike (Route 30). All patients are treated with the highest level of courtesy and accommodation. Referrals from physicians are appreciated and treated with confidentiality. No patients seen on referral for our clinical trials will be seen in the office for rheumatic care outside of the clinical trial unless the referring physician personally calls and requests it. This is the policy of the Center in order to avoid all conflicts of interest and the relationship of the referring physicians and their patients.
Research Studies our site has conducted:
Asthma
Sponsor: Skye Pharma
Protocol: SKY2028-3-001
Phase: III
Year: 2005
A randomized, Double Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-center, 12 week study comparing the safety and efficacy of Fluticasone and Formoterol Combination (Fluti Form TM 100/10 ug twice daily) in a single inhaler (sky pharma HFA pMDI) with the administration of Placebo or Fluticasone 100 ug twice daily alone in adolescent and adult patients with mild to moderate asthma.
Chronic Low Back Pain
Sponsor: DOV
Protocol: DOV-075-020-US
Phase: III
Year: 2004
Double blind, placebo-controlled randomized study of Bicifadine in the treatment of Chronic Low Back Pain.
Sponsor: Johnson & Johnson
Protocol: R331333-PAI-3004
Phase: III
Year: 2006
A Randomized, Double-Blind, Active-Controlled, Parallel Group, 90 Day safety study of CG5503 Immediate Release or Oxycodone Immediate Release, in subjects with chronic pain from Low Back Pain or Osteoarthritis of the Hip or Knee.
Sponsor: Johnson & Johnson
Protocol: R331333-PAI-3011
Phase: III
Year: 2007
A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm with controlled Adjustments of Dose to Evaluate the Efficacy and Safety of CG5503 Extended Release (ER) in subjects with Moderate to Severe Chronic Low Back Pain.
Sponsor: Johnson & Johnson
Protocol: R331333-PAI-3010
Phase: III
Year: 2007
Open-Label Extension, Single Arm, Flexible-Dosing with CG5503 Extended-Release (ER) in subjects with moderate to Severe Chronic Pain.
COPD
Sponsor: Altana Pharma
Protocol: BY217-M2-124
Phase: III
Year: 2006
Effect of Roflumilast, on exacerbation rate in patients with COPD. A 52 week, Double-Blind Study with 500 mcg Roflumilast once daily versus placebo.
Fibromyalgia
Sponsor: Forest Research Institute
Protocol: MLN-MD-03
Phase: III
Year: 2006
A pivotal, multi center, double blind, randomized, placebo controlled monotherapy study of Milnacipran for the treatment of fibromyalgia.
Sponsor: Forest Research Institute
Protocol: MLN-MD-06
Phase: III
Year: 2006
A Multicenter, Open-Label, Flexible Dosing Study of Milnacipran for the treatment of Fibromyalgia.
Insomnia
Triazolam and Temazepam
Insomnia treatment study, comparing Triazolam and Temazepam.
Lupus
Sponsor: MedImmune
Protocol: MI-CP179
Phase: IIA
Year: 2008
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the safety and tolerability of multiple subcutaneous doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in subjects with Systemic Lupus Erythematosus.
Opioid-Induced Bowel Dysfunction
Mucosa Trial
Double blind study evaluating Cytotec plus NSAID and the risk of GI
complications.
Sponsor: Glaxo Smith Kline
Protocol: SB-767905/011
Phase: II B
Year: 2003
Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.
Sponsor: Glaxo Smith Kline
Protocol: SB/767905-012/014
Phase: III
Year: 2003
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Alvimopan for 12 Weeks and 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
Sponsor: Glaxo Smith Kline
Protocol: ABD104225
Phase:
Year: 2004
Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naive Subjects with Pain Treated with Opioid Therapy.
Sponsor: Wyeth
Protocol: 3200A3-200-WW
Phase: III
Year: 2006
A Multicenter, Randomized, Double-Blind, Parallel-Group, study of Oral MOA-728 for the treatment of Opioid-Induced Bowel Dysfunction in subjects with Chronic Non-Malignant Pain.
Osteoarthritis
Sponsor: Novartis
Study: Voltar
Phase: III
Twelve patients were enrolled for a clinical trial of Voltaren, a new NSAID.
Sponsor: Glaxo Smith Kline
Study: Nabumetone
Phase: III
Study comparing a new NSAID, Nabumetone, to another NSAID in a clinical trial.
Sponsor: Merck
Study: Rofecoxib
Phase: IIb/III
Randomized double blind multicenter study evaluating the tolerability and effectiveness of Rofecoxib versus Naproxen in patients with osteoarthritis.
Sponsor: Merck
Protocol: 066-01
Phase: III
Year: 2002
A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rheumatoid Arthritis.
Sponsor: Merck
Protocol: 071-01
Phase: III
Year: 2003
A 12 week, Randomized, Placebo and Active Comparator Controlled, Parallel Group, Double Blind Study to assess the safety and efficacy of Etoricoxib 30 mg verse Ibuprofen 2400 mg in patients with osteoarthritis.
Sponsor: Pain Therapeutics Inc.
Protocol: PTI-801-XH
Phase: III
Year: 2003
A Multi-center, Randomized, Double-Blind, Active- and Placebo-Controlled, Efficacy and Safety Study of Oxycodone HCI and Low Dose Naltrexone HCI in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee.
Sponsor: Merck
Protocol: 077-00/COX553
Phase: III
Year: 2004
26 Week Randomized, Placebo-and Active-Comparator-Controlled, Parallel-Group, Double-Blind, Two Part study to assess the Safety and Efficacy of Etoricoxib vs. Celecoxib in Patients with Osteoarthritis.
Sponsor: Purdue Pharma
Protocol: OXY4003
Phase: IV
Year: 2004
Multicenter Usual Care Open-Labeled Randomized-Parallel-Group Trial Comparing the Impact of Therapy with Oxycontin vs. Usual Care in Moderate to Severe Osteoarthritis of the Hip or Knee.
Sponsor: Novartis
Protocol: VOSG-PN-310
Phase: III
Year: 2004
A 12 Week, Randomized, Double-Blind, Multicenter, Vehicle-Controlled, Parallel Group to Assess the Efficacy and Safety of the Diclofenic Sodium Gel 1% for the Relief of Signs and Symptoms in Patients with Osteoarthritis of the Knee.
Sponsor: Labopharm
Protocol: MDT3-005
Phase: III
Year: 2004
A Two-Arm study Comparing the Analgesic Efficacy and Safety of Tramadol HCI Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the knee.
Sponsor: Merck
Protocol: MK-072-00
Phase: III
Year: 2005
A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Extoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis.
Sponsor: MK-0663-066
Protocol: MK-0663-066
Phase: III
Year: 2005
A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib patients with Osteoarthritis or Rheumatoid Arthritis.
Sponsor: Johnson & Johnson
Protocol: R331333-PAI-3004
Phase: III
Year: 2006
A Randomized, Double-Blind, Active-Controlled, Parallel Group, 90 Day safety study of CG5503 Immediate Release or Oxycodone Immediate Release, in subjects with chronic pain from Low Back Pain or Osteoarthritis of the Hip or Knee.
Sponsor: Riant
Protocol: RN624-CL006
Phase: II
Year: 2006
A Randomized, Parallel-Arm, Placebo-Controlled, Double-Blind, Multiple Dose Study of the safety and efficacy of RN624 in adults with moderate to severe pain due to Osteoarthritis of the knee.
Sponsor: Biovail
Protocol: TMX-301
Phase: III
Year: 2006
A Open-Label, Long Term Safety Study of Tramadol Hydrochloride Extended Release and Meloxicam QD Combination in the Treatment of Moderate to Moderately Severe Pain Associated with Osteoarthritis.
Sponsor: Pfizer
Protocol: A3191172
Phase: IV
Year: 2006
A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients with or at high risk for cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.
Sponsor: CombinatoRx
Protocol: CRX-102-006
Phase: II
Year: 2007
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to evaluate the efficacy of CRX-102 in subjects with Symptomatic Knee Osteoarthritis.
Sponsor: CombinatoRx
Protocol: CRX-102-006E
Phase: II
Year: 2007
A Randomized, Double-Blind, Multi-Center, 1 year extension study to evaluate the long-term safety, tolerability and effectiveness of CRX-102 in subjects with Symptomatic Knee Osteoarthritis.
Sponsor: Pfizer
Protocol: A4091025
Phase: III
Year: 2009
A Multi-Center, Randomized, Double-Blind, Controlled Study of the long term analgesic efficacy and safety of Tanezumab alone or in combination with non-steroidal Anti-Inflammatory drugs (NSAIDS) versus NSAIDS alone in patients with osteoarthritis of the knee or hip.
Osteoporosis
Sponsor: Merck
Protocol: MK-217
Phase: IV
Year: 2000
A Multicenter, Open Label, Randomized, Crossover, Preference Study of oral Alendronate Sodium 70 mg once weekly and 10 mg once daily in postmenopausal women with osteoporosis.
Sponsor: Eli Lilly & Company
Protocol: B3D-US-GHCQ
Year: 2005
Direct assessment of non vertebral fractures in community experience (DANCE).
Rheumatoid Arthritis
Sponsor: Ortho-McNeil, Inc.
Study: Ultram
A double blind, randomized, parallel group, multicenter comparison of the efficacy and safety of Mycophenolate mofetil p.o. (Xg b.i.d.) and placebo in patients with active rheumatoid arthritis (six month efficacy study) who are candidates for immunosuppressive therapy for rheumatoid arthritis.
Sponsor: Roche
Study: Meloxicam
A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam with Naproxen and placebo on patients with rheumatoid arthritis.
Sponsor: Merck
Study: Rofecoxib
Randomized double blind multicenter study evaluating the tolerability and
effectiveness of Rofecoxib versus Naproxen in patients with rheumatoid arthritis.
Sponsor: Wyeth
Protocol: RADIUS 1
Year: 2002
Rheumatoid Arthritis DMARD Intervention and Utilization Study.
Sponsor: Merck
Protocol: 066-01
Phase: III
Year: 2002
A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rheumatoid Arthritis.
Sponsor: Wyeth
Protocol: RADIUS 2
Year: 2003
Rheumatoid Arthritis DMARD Intervention and Utilization Study.
Sponsor: Merck
Protocol: MK-0663
Phase: III
Year: 2003
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib vs. Diclofenac Sodium in Patients with Rheumatoid Arthritis.
Sponsor: Hoffmann La Roche
Protocol: WA18063
Phase: III
Year: 2005
A randomized, double blind placebo controlled parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.
Sponsor: Arakis
Protocol: P-AD452-022
Phase: II
Year: 2005
A randomized, double-blind, multicenter, placebo controlled, dose ranging parallel group study to compare the efficacy, safety and tolerability of three strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking Methotrexate.
Sponsor: Hoffmann La Roche
Protocol: WA18696
Phase: III
Year: 2005
Long term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA Core Studies.
Sponsor: Merck
Protocol: MK-072-00
Phase: III
Year: 2005
A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Extoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis.
Sponsor: MK-0663-066
Protocol: MK-0663-066
Phase: III
Year: 2005
A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib patients with Osteoarthritis or Rheumatoid Arthritis.
Sponsor: Genentech
Protocol: U3384g
Phase: III
Year: 2006
A randomized, double blind, placebo controlled, multi center study of re-treatment with Rituximab in subjects with rheumatoid arthritis receiving background methotrexate.
Sponsor: Hoffmann La Roche
Protocol: WA17824
Phase: III
Year: 2006
A randomized, double blind, double dummy, parallel group study of the safety and efficacy of MRA monotherapy vs. methotrexate monotherapy, in patients with active rheumatoid arthritis.
Sponsor: Pfizer
Protocol: A3191172
Phase: IV
Year: 2006
A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients with or at high risk for cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.
Sponsor: Genentech
Protocol: U3924g
Phase: III
Year: 2007
An Open-Label, Prospective Study of the safety of Rituximab in combination with other disease-modifying Anti-Rheumatic Drugs in subjects with Active Rheumatoid Arthritis.
Sponsor: Genentech
Protocol: WA20494/ACT3985g
Phase: III
Year: 2007
A Program investigating two dose regimens of Rituximab, two infusions of either 500 mg or 1000 mg separated by 14 days between treatments is underway in patients with Rheumatoid Arthritis unresponsive to Methotrexate and in patients with Rheumatoid Arthritis but naive to Methotrexate Treatment.
Sponsor: Genentech
Protocol: WA20495/ACT3986g
Phase: III
Year: 2007
A Randomized, Double-Blind, Parallel Group, International Study to evaluate the safety and efficacy of Ocrelizumab, compared to Placebo in patients with Active-Rheumatoid Arthritis who have inadequate response to at least one Anti-TNF a Therapy.
Sponsor: Pfizer
Protocol: A7701005
Phase: II
Year: 2007
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of CP-195543 and Celecoxib Dual Therapy in the treatment of the Signs and Symptoms of Rheumatoid Arthritis in Subjects who are inadequately controlled on Methotrexate.
Sponsor: CombinatoRx
Protocol: CRX-102-007
Phase: II B
Year: 2007
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRX-102 over each of its components when given to subject with active Rheumatoid Arthritis.
Sponsor: Cypress
Protocol: CYP-D-001
Phase: N/A
Year: 2009
Applications for Methotrexate Optimization in Rheumatoid Arthritis.
Sponsor: Roche
Protocol: ML22533
Phase: IIIb
Year: 2009
An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic DMARDs in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs.
Sponsor: Roche
Protocol: WA19926
Phase: III
Year: 2009
A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe rheumatoid arthritis.
If you have any questions, please call 856-547-8004 or e-mail fisherresearch@markfishermd.com